Denhoy explains, “NuVasive put up a $2mn/$0.01 rev./EPS beat and raised guidance for the year. The top-line (+8.6% ex-FX, ex-NSO) was driven by continued positive trends in Hardware and Support and another very strong quarter for the international business ”
The analyst raises his FY16 sales guidance to $962mn and includes $27mn from Biotronic.
According to TipRanks, Raj Denhoy is ranked #39 of 4,083 analysts. He maintains a success rate of 75% and realizes an average return of 14.9%